Metastatic Cervical Cancer Clinical Trials
22 clinical trials for Metastatic Cervical Cancer across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer — RECRUITING · PHASE2
- PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer — RECRUITING · PHASE2
- A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer — RECRUITING · PHASE3
- Pembrolizumab and Lenvatinib in Advanced Cervical Cancer — RECRUITING · PHASE2
- Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy — RECRUITING
- Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer — NOT_YET_RECRUITING
- PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer — TERMINATED · PHASE4
- Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer — ACTIVE_NOT_RECRUITING · NA
- Dostarlimab and Cobolimab in Advanced Cervical Cancer — ACTIVE_NOT_RECRUITING · PHASE2
- QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer — NOT_YET_RECRUITING
- Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer - A Multicenter Retrospective Longitudinal Study — OTHER
- Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer — TERMINATED · PHASE1
- A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer — COMPLETED · PHASE2
- Safety of Effivia®, a Bevacizumab Biosimilar — COMPLETED
- Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy — WITHDRAWN · PHASE2
- SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer — COMPLETED · PHASE2
- QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer — OTHER · PHASE3
- Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) — WITHDRAWN · PHASE3
- Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer — TERMINATED · PHASE2
- HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib — TERMINATED
- Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer — COMPLETED · PHASE2
- Hydralazine Valproate for Cervical Cancer — OTHER · PHASE3
Refine this search